Golden Biotechnology Corp. (GBC,”GoldenBiotech”) (TPEx4132) is an advanced pharmaceutical development company focused on meeting the pressing demand for effective medications among patients with critical medical needs. With over a decade of experience and technical know-how in cancer drug research and manufacturing, GoldenBiotech stands as one of the few organizations that are capable of independently developing NCEs (New Chemical Entities) as novel drugs. We possess comprehensive expertise in the complete process of drug development. GBC conducted comprehensive preclinical trials in collaboration with several internationally renowned research institutions and initiated research and multi-national, multi-center clinical trials targeting indications such as cancer, cardiovascular diseases, neurodegenerative diseases, autoimmune diseases, and COVID-19 virus infection. Our ongoing research centers around a brand-new NCE small molecule drug called Antroquinonol, which exhibits remarkable efficacy and safety. Antroquinonol has already completed several Phase 2 clinical trials, including studies on non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), pancreatic cancer, and COVID-19.